Heidelberg Pharma AG (ETR:HPHA)

Market Cap	143.15M
Revenue (ttm)	3.04M
Net Income (ttm)	-26.18M
Shares Out	46.78M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,561
Average Volume	9,828
Open	3.110
Previous Close	3.150
Day's Range	2.950 - 3.130
52-Week Range	2.150 - 5.360
Beta	0.87
RSI	55.49
Earnings Date	Mar 23, 2026

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic cas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 114
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: HPHA

Financial Performance

In 2024, Heidelberg Pharma AG's revenue was 6.85 million, a decrease of -30.53% compared to the previous year's 9.86 million. Losses were -19.38 million, -4.74% less than in 2023.